100% Quality Guarantee
PhD-Level Technical Support
Anti-CD52 alemtuzumab biosimilar mAb HDBS0030
Key Features

Alemtuzumab Biosimilar (CD52) Antibody (HDBS0030)

SKU HDBS0030
Antibody Type Biosimilar Reference Antibody
Applications Drug Development
Applications Pharmacokinetics
Disease Area Chronic Lymphocytic Leukemia
Disease Area Transplantation
Protein CD52
Reactivity Human
Host Species Humanized
Isotype IgG1
$569

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheet

Alemtuzumab Biosimilar (CD52) Antibody (HDBS0030)

Based on the information provided in the URL, I will provide a product description based on the specific product mentioned.The CD52 (Alemtuzumab) Biosimilar Monoclonal Antibody (HDBS0030) is a cutting-edge research tool designed for studying the CD52 cell surface molecule. CD52 is a protein found on the surface of certain immune cells, and plays a crucial role in immune regulation. This antibody, developed as a biosimilar to Alemtuzumab, a well-known therapeutic antibody targeting CD52, is highly specific and reactive with human samples.Validated for use in various research applications including Western blotting, this monoclonal antibody enables the detection and analysis of CD52 in different cell types. Its high affinity binding to CD52 makes it an excellent tool for studies in immunology, cancer research, and other areas where CD52 is implicated.

CD52 is known for its role in immune cell function and its potential as a target for therapeutic intervention in diseases such as cancer, autoimmune disorders, and inflammatory conditions. By using this monoclonal antibody, researchers can deepen their understanding of CD52's function and explore its potential as a target for novel treatments in these disease contexts.Overall, the Anti-CD52 (Alemtuzumab) Biosimilar Monoclonal Antibody (HDBS0030) is a valuable tool for researchers looking to delve into the complexities of immune regulation and explore new avenues for therapeutic development in

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose